The company has initiated seven clinical trials of IMP321 over the last four years, and in January reported positive interim results from an ongoing Phase I/II trial in metastatic breast carcinoma...Our positive results in chemo-immunotherapy have encouraged us to engage in discussions with potential partners over Immutep's plans for IMP321," he said.

We are very pleased to see Biocortech's test entering clinical development," said the company's CEO, Dinah Weissmann...BioAlliance said it has initiated the development of a debossed tablet to meet the requirement and that it aims to resubmit an application for Loramyc shortly.

Three new companies moved into the campus in 2008, increasing the total number of people employed there to 550.

According to the CEO of NicOx, Michele Garufi, taking NCX 6560 into clinical development reflects the company's determination to "expand our drug discovery projects in the cardiometabolic area, where nitric oxide plays a fundamental physiological role...Coreg CR microparticles are produced by Flamel at its production facility in Pessac, in south-western France.

The clinical batches for the initial trial of the anti-CD20 antibody were produced by MAbgène, of Alès, which LFB took over in 2007...LFB is a pharmaceutical company that specializes in plasma-derived medicinal products in three therapeutic fields - immunology, homeostasis and intensive care - and said it expects to receive marketing authorization later this year for a new nanofiltered fibrinogen.

Innate, Vivalis Collaborate in Monoclonal Antibodies Innate Pharma SA and Vivalis signed a joint collaboration and commercial license agreement covering the use of the Vivalis EB66 cell line for developing an industrial process to manufacture clinical batches of IPH 4101, a novel cytotoxic monoclonal antibody developed by Innate Pharma for the treatment of rare cutaneous lymphomas such as Sezary syndrome and transformed mycosis fungoides...Innate Pharma will retain worldwide development and

The two companies earlier halted clinical development of LFA-1 for the treatment of systemic immuno-inflammatory diseases after hepatotoxic side-effects were observed following oral administration...Laboratoires Théa is specialized in ophthalmology, and according to Jean-Frédéric Chibret, company president, this is a "very promising project" that could "open the door to a novel therapeutic class with multiple possibilities for ophthalmologic diseases."

The interim results showed a clinical response rate of 50 percent compared to 25 percent with paclitaxel alone, as well as a robust immune response in clinically responsive patients...for the advanced development stages of IMP321, as we continue to collect data from this study at the highest dose," he said.

Clinical trial results to date have demonstrated that it has lower toxicity than calcitriol, the natural active metabolite of vitamin D3, leading Hybrigenics to believe that inecalcitol could be administered at higher doses than calcitriol, making it a more effective therapy for prostate cancer...Cellectis has been developing meganuclease-based genome surgery since 2000 and has established an industrial platform for generating custom meganucleases targeted to any predefined gene.